NASDAQ · MRTX
Healthcare · Biotechnology
$58.70
Down-$0.10 (-0.17%)
Updated Sep 11, 2026, 7:53 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
MRTX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning MRTX.
MRTX research
Company profile and research snapshot.
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 20, 2023 | Citigroup | Neutral | — |
| Nov 7, 2023 | Leerink Partners | Market Perform | — |
| Nov 7, 2023 | Stifel | Hold | — |
| Oct 10, 2023 | Piper Sandler | Neutral | — |
| Oct 9, 2023 | B. Riley Securities | Neutral | — |
No generated briefing is available yet.
Zacks Investment Research · Jan 11, 2024
Mirati's (MRTX) Krazati gets the European Commission's conditional marketing approval for treating adult patients with KRASG12C-mutated advanced non-small cell lung cancer.
Zacks Investment Research · Jan 3, 2024
Bristol Myers' (BMY) repotrectinib is under review in the European Union for the treatment of locally advanced or metastatic ROS1-Positive NSCLC and NTRK-positive solid tumors.
Zacks Investment Research · Dec 27, 2023
Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval.
Benzinga · Dec 20, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Raymond James boosted Teleflex Incorporated (NYSE: TFX) price target from $227 to $271. Raymond James analyst Jayson Bedford maintained an Outperform rating. Teleflex shares rose 0.2% to close at $253.83 on Tuesday. See how other analysts view this stock. Citigroup increased the price target for MacroGenics, Inc. (NASDAQ: MGNX) from $7 to $13. Citigroup analyst Yigal Nochomovitz upgraded the stock from Neutral to Buy. MacroGenics shares gained 6.3% to close at $9.23 on Tuesday. See how other analysts view this stock. Stifel raised the price target for Lowe's Companies, Inc. (NYSE: LOW) from $235 to $240. Stifel analyst W. Andrew Carter downgraded the stock from Buy to Hold. Lowe's shares gained ...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MRTX.
No results
No recent SID articles mention MRTX.
